IκB kinase-beta inhibitor attenuates hepatic fibrosis in mice.

Abstract

AIM:

To investigate the anti-fibrosis effect of IκB kinase-beta inhibitor (IKK2 inhibitor IMD0354) in liver fibrosis.

METHODS:

Twenty male C57BL6 mice were divided into four groups. Five high-fat fed mice were injected with lipopolysaccharide (LPS, 10 mg/kg) intraperitoneally and five high-fat fed mice were without LPS injection to build models of liver injury, and the intervention group (five mice) was injected intraperitoneally with IKK2 inhibitor (IMD 30 mg/kg for 14 d), while the remaining five mice received a normal diet as controls. Hepatic function, pathological evaluation and liver interleukin-6 (IL-6) expression were examined. Western blotting and real-time polymerase chain reaction were used to detect the expressions of nuclear factor-κB (NF-κB), alpha-smooth muscle actin (α-SMA), tumor growth factor-beta1 (TGF-β1), tumor necrosis factor-alpha (TNF-α), typeIand type III collagen proteins and mRNA.

RESULTS:

A mouse model of liver injury was successfully established, and IMD decreased nuclear translocation of NF-κB p65 in liver cells. In the IMD-treated group, the levels of alanine aminotransferase (103 ± 9.77 μ/L vs 62.4 ± 7.90 μ/L, P < 0.05) and aminotransferase (295.8 ± 38.56 μ/L vs 212 ± 25.10 μ/L, P < 0.05) were significantly decreased when compared with the model groups. The histological changes were significantly ameliorated. After treatment, the expressions of IL-6 (681 ± 45.96 vs 77 ± 7.79, P < 0.05), TGF-β1 (Western blotting 5.65% ± 0.017% vs 2.73% ± 0.005%, P < 0.05), TNF-α (11.58% ± 0.0063% vs 8.86% ± 0.0050%, P < 0.05), typeIcollagen (4.49% ± 0.014% vs 1.90% ± 0.0006%, P < 0.05) and type III collagen (3.46% ± 0.008% vs 2.29% ± 0.0035%, P < 0.05) as well as α-SMA (6.19 ± 0.0036 μ/L vs 2.16 ± 0.0023 μ/L, P < 0.05) protein and mRNA were downregulated in the IMD group compared to the fibrosis control groups (P < 0.05).

CONCLUSION:

IKK2 inhibitor IMD markedly improved non-alcoholic fatty liver disease in mice by lowering NF-κB activation, which could become a remedial target for liver fibrosis.

• Authors: Jue Wei, Min Shi, Wei-Qi Wu, Hui Xu, Ting Wang, Na Wang, Jia-Li Ma, Yu-Gang Wang
• Journal: World journal of gastroenterology (World J Gastroenterol) Vol. 17 Issue 47 Pg. 5203-13 (Dec 21 2011) ISSN: 2219-2840 [Electronic] United States
• PMID: 22215946 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Benzamides
• Collagen Type I
• Collagen Type III
• Interleukin-6
• Lipopolysaccharides
• NF-kappa B
• Transforming Growth Factor beta1
• Tumor Necrosis Factor-alpha
• N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide
• Aspartate Aminotransferases
• Alanine Transaminase
• I-kappa B Kinase

Topics

• Alanine Transaminase (blood)
• Animals
• Aspartate Aminotransferases (blood)
• Benzamides (therapeutic use)
• Collagen Type I (genetics, metabolism)
• Collagen Type III (genetics, metabolism)
• Disease Models, Animal
• Fatty Liver (drug therapy, metabolism, pathology)
• I-kappa B Kinase (antagonists & inhibitors)
• Interleukin-6 (metabolism)
• Lipopolysaccharides (administration & dosage)
• Liver Cirrhosis (drug therapy, metabolism, pathology)
• Male
• Mice
• Mice, Inbred C57BL
• NF-kappa B (metabolism)
• Non-alcoholic Fatty Liver Disease
• Transforming Growth Factor beta1 (genetics, metabolism)
• Tumor Necrosis Factor-alpha (metabolism)